Status:
COMPLETED
Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC)
Lead Sponsor:
Queen Elizabeth Hospital, Hong Kong
Conditions:
Bowel Preparation Solutions
Colonoscopy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
4L split dose PEG is the gold standard for bowel preparation, however it comes with poor tolerability and poor compliance. Combination of PEG with different agent is useful in reducing total volume, i...
Detailed Description
This is a prospective, randomized, single-center, single-blinded, non-inferiority trial. Participants with out patient colonoscopy arranged will be included and randomized in a 1:1 ratio to receive e...
Eligibility Criteria
Inclusion
- Patient who mentally capable to consent for participating the trial
- 18 - 65 years old
- Scheduled for 1st colonoscopy
- Elective outpatient colonoscopy
Exclusion
- Prior colorectal or abdominal-pelvic surgery
- Inflammatory bowel disease
- Active bowel condition eg intestinal obstruction
- Gastrointestinal disorders eg active ulcer, gastric outlet obstruction, gastroparesis and hypomotility syndrome
- Recent myocardial infarction, congestive heart failure, uncontrolled hypertension
- Renal dysfunction, hepatic disease
- Patient on long term tranquilizer, anti-spasmodic, prokinetic, laxative or antidiarrhoeal agents
- Hypersensitivity to PEG or SPMC solution
- Pregnant or breastfeeding women
- Inability to give informed consent
Key Trial Info
Start Date :
December 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT04474002
Start Date
December 7 2020
End Date
December 31 2022
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital
Kowloon, Hong Kong